Mosunetuzumab for CLL MRD Clearance

Must have received: BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib) — first- or second-line

On continuous BTKi therapy for > 12 months, including > 2 months at a stable dose. The BTKi is the first- or second-line therapy for CLL.

Must have received: BCL2 inhibitor (venetoclax) — first- or second-line

Completed BCL2i-based therapy < 12 months of enrollment. BCL2i-based therapy must be the most recent CLL therapy prior to enrollment. BCL2i must have been given for at least 6 months for patients who were intolerant to a BCL2i and stopped the treatment without disease progression. For all others, at least 12 cycles of BCL2i therapy are required. BCL2i-based regimens include venetoclax plus obinutuzumab (VO) or rituximab (VR), and the combination of a BTKi + a BCL2i +/- anti-CD20mAb.

Cannot have received: CAR-T cell therapy

Exception: within 30 days of starting study therapy

Prior treatment with chimeric antigen receptor T-cell therapy within 30 days of starting study therapy

Cannot have received: radioimmunotherapy

Exception: within 12 weeks of starting study therapy

radioimmunotherapy within 12 weeks of starting study therapy